Introduction
The assessment of sexual dysfunction is as problematical as the actual concept of sexuality itself. The French philosopher, Michel Foucault defined sexuality as a constellation of phenomena, including the stimulation of bodies; the intensification of pleasure sensations; and encouraging communication and development of knowledge. He acknowledged the central issue of the power struggle between men and women, old and young, parents and children, teachers and students. He also considered that sexuality was dependent on place, culture and time. Certainly, sexuality is a complex entity and from the urologists' perspective several aspects need to be considered, such as desire, libido, pleasure, sexual life, intercourse, erection, ejaculation, orgasm, happiness and bother.
Why should we be concerned about sexuality in men with BPH?
Sexuality is an important aspect of quality of life in elderly people. With the increasing life expectancy of men worldwide, there is an ever increasing number of sexually active men consulting for lower urinary tract symptoms (LUTS). The evidence for the link between the severity of LUTS and sexual dysfunction has been established and it is also acknowledged that different treatments for benign prostatic hyperplasia (BPH) can affect sexuality to different extents, either positively or negatively, reversibly or irreversibly. However, sexuality is generally not discussed in detail during the patientdoctor dialogue and the incidence of sexual dysfunction in men with BPH is likely to be underestimated. Many doctors are reluctant to discuss sexual dysfunction with their patients, in part due to lack of specific training but also because of not wanting to cause embarrassment to the patient. Doctors may also not be aware of the impact sexual dysfunction has on both patients and their partners. In one study of 62 men, 97% reported sexual concerns, but only 19% raised the topic themselves. 1 The majority said they would prefer to have the doctor initiate the discussion.
Definition of sexuality
Male sexuality includes at least six domains: erection, ejaculation, sexual intercourse, orgasm, libido and overall sexual life. These six domains can be measured in two different dimensions as shown in Table 1 . The functional dimension takes into account symptoms and dysfunctions in each of the domains, such as the presence of erectile dysfunction (ED) or retrograde ejaculation. The second dimension evaluates the impact of the sexual domain on quality of life, ie pleasure/happiness vs trouble/anxiety. The two dimensions are complementary as there is no direct correlation between symptoms and dysfunctions and their impact on patients' quality of life. For example, it is well known that the degree to which retrograde ejaculation is regarded as bothersome varies considerably among individual patients. For these reasons, these two dimensions must be measured separately in a complementary manner.
Assessment of sexuality
Sexuality can be measured through a simple patientdoctor dialogue, although this may be inappropriate as sexuality is a hidden domain. Such methods will invariably underestimate the report of potential sexual dysfunction. It is important in such dialogues for the doctor to explain the distinction between loss of libido, loss of erection and ejaculatory disturbance. In conjunction with a patient interview, sexuality can be measured through self-administered questionnaires, a number of which have been validated. It is imperative that such tools take into consideration both the quantitative and qualitative aspects of sexuality, as there is no linear relationship between the quantified result and the quality perceived by the patient.
The questionnaires must be adapted: they must be multidimensional; explore different domains of sexuality; have good sensitivity to clinical change; and be easy to administer with not too many questions. Psychometric validation of the questionnaire is essential before it is put to general use. The psychometric properties that need to be verified include: validity, reliability, sensitivity and discriminatory value. Such a process, although complicated, is essential in the interpretation of results. Six examples of most commonly used adapted and validated instruments are shown in Table 2 . All of the instruments have been used in clinical studies involving patients with symptomatic BPH or in epidemiological studies in patients with LUTS.
BMSFI
The Brief Male Sexual Function Inventory (BMSFI) has been developed specifically to measure male sexual function. 2 It is an 11-item questionnaire scale that assesses several components of male sexual function, including sexual drive, erection, ejaculation, problem assessment and overall satisfaction. The major advantages of this scale are:
A relative high degree of internal consistency and testretest reliability. Adequate discriminatory validity for the three domains (erectile function, problems, overall satisfaction). Ease of use.
Potential limitations are the restricted evaluation of erectile and orgasmic function and lack of evidence concerning sensitivity or treatment responses.
DAN-PSS
The Danish Prostatic Symptom Score (DAN-PSS) is based on the patient's information about the presence and severity of 12 symptoms related to bladder storage and voiding functions (symptom score). 3 For each question, the patient can choose one of four answers, with each symptom having a question relating to severity and to degree of bother. This instrument appears to be reliable, valid and responsive; median test -retest reliability was shown to be 83.5%. It has been recommended for assessing the severity of symptoms among patients presenting with LUTS associated with BPH and in the follow-up after intervention.
Three additional questions relating to sexual function have been added to the original DAN-PSS. These relate to the ability to obtain an erection, to ejaculation and any pain/discomfort during ejaculation. Again each question is split into the severity of the symptoms and how bothered the patient is by it. This modified form of the DAN-PSS has been used to assess sexual function in an unselected population referred to hospital for treatment of BPH. 4 A total of 401 patients in age groups < 50 y, 50 -59 y, 60 -69 y, > 69 y completed the questionnaire. Analysis of the data showed that the incidence of ED increased with age and that the related bother was much higher in young males. There was also a correlation between increasing age and smaller ejaculation volume; however, the related bother was low. Around 15% of men experienced pain/discomfort during ejaculation, with a high bother factor; this was independent of age. The IIEF has been translated into 23 languages and is currently in use in several large-scale multinational trials. The major advantages of this measure are its relative brevity and ease of use, inclusion of multiple domains of sexual function and strong psychometric profile. Potential disadvantages are the limited assessment of certain domains (for example, sexual desire and orgasmic function), restricted time-frame (4 weeks) and uncertain validity in selected populations (for example, psychiatric patients).
A study has been conducted to evaluate the erectile function domain of the IIEF as a diagnostic tool to discriminate between men with and without ED and to develop a clinically meaningful gradient of severity for ED. 8 A total of 1035 men with and 116 men without ED who reported attempting sexual activity were evaluated using data generated from four clinical trials of sildenafil citrate and two control samples. For a 0.5 prevalence rate of ED, the optimal cut-off score was 25, with men scoring less than or equal to 25 classified as having ED and those scoring above 25 as not having ED (sensitivity 0.97, specificity 0.88). Sensitivity analyses revealed a robust statistical solution that was well supported with different assumed prevalence rates and several cross-validations. The severity of ED was classified into five categories: no ED (erectile function score 26 -30), mild (score 22 -25), mild to moderate (score 17 -21), moderate (score 11 -16), and severe (score 6 -10). Substantial agreement was shown between these predicted and 'true' classes. It was concluded that the erectile function domain possesses favourable statistical properties as a diagnostic tool, not only in distinguishing between men with and without ED, but also in classifying levels of ED severity.
Clinical validation of the erectile function domain using self-rated assessments of ED severity has recently been conducted. 9 A total of 247 men with clinically diagnosed ED assessed their degree of ED as severe, moderate, minimal/mild, or no problem at baseline and after treatment. They also responded to the six questions of the erectile function domain of the IIEF, with the total score indicating the degree of ED. Analysis showed a moderate-to-high correlation between the patients' selfassessment of erectile function and the erectile function domain of the IIEF, providing a validation of this domain for the reliable diagnostic classification of ED severity.
More recently, an abridged five-item version of the 15-item IIEF was developed -the IIEF-5 -to diagnose the presence and severity of ED. 10 The five items selected were based on ability to identify the presence or absence of ED and on adherence to the National Institute of Health's definition of ED. These items focused on erectile function and intercourse satisfaction. For 1152 men (1036 with ED, 116 controls) analysed, a receiver operating characteristic curve indicated that the IIEF-5 is an excellent diagnostic test. Based on equal misclassification rates of ED and no ED, a cut-off score of 21 provided the best discriminant value (sensitivity ¼ 0.98, specificity ¼ 0.88). ED was classified into five severity levels, ranging from none (22 -25) through to severe (5 -7). Substantial agreement existed between the predicted and 'true' ED classes. These data suggest that the IIEF-5 possesses favourable properties for detecting the presence and severity of ED.
ICSsex
The International Continence Society sex (ICSsex) is part of a longer questionnaire, the ICSBPH, which was developed for the ICS-Benign Prostatic Hyperplasia (ICS-BPH) Study. 11 The ICS-BPH study questionnaire includes the ICSmale questionnaire, which consists of 22 questions on 20 urinary symptoms, and, for most questions, the amount of bother that the symptom causes. It also includes the ICSQoL, 11 to assess issues concerning quality of life, and the ICSsex. Both the ICSmale and the ICSQoL have been shown to be psychometrically valid and reliable. 11, 12 The ICSsex consists of four questions relating to the effect of LUTS on the patient's sex life, whether the patient has erections or ejaculation and any pain/discomfort experienced during ejaculation. In common with other questionnaires, it also assesses the degree of bother experienced by the patient because of these symptoms.
The ICS-BPH Study investigated 423 men aged 40 y and over in a community population in the UK and 1271 urology clinic attenders aged 45 y and over in 12 countries. The ICSsex questionnaire identified a high prevalence of sexual dysfunction. In the community, the incidence of reduced erections was 53%, reduced ejaculation 47% and pain on ejaculation 5%; the equivalent numbers in the clinic sample were: 60, 62 and 17%, respectively. The main objective of the study was confirmed, in that sexual dysfunction was shown to be strongly associated with LUTS.
Urolife TM BPHQoL 20 and the BPHQoL9
The Urolife TM Benign Prostatic Hyperplasia Quality of Life 20 (BPHQoL 20) consists of 20 questions scored on a 10 cm visual analogue scale. 13 Included are six questions on each of the following categories: physical/functional status, mental health status, social life status; two questions relate to overall health status. This questionnaire has been validated in both cross-sectional and longitudinal studies in compliance with World Health Organisation recommendations and Agency for Health Care Policy and Research (AHCPR) guidelines.
This questionnaire has been used in a 3-y prospective, open label study of 3228 clinical BPH patients in General Practice who were treated with alfuzosin (immediate release formulation). 14 Of 2579 patients who completed the study, the quality of life score was significantly increased by 45.4% at 12 months and this improvement was maintained up to 36 months. These results indicate that alfuzosin improves quality of life, including sexual function during 3 y of treatment.
The BPHQoL9 is a modification of the Urolife TM BPHQoL 20. 15 Mathematical modelling identified nine of the original 20 questions that would minimise the loss of information and maintain the three-dimensional aspect of the longer questionnaire (Table 3 ). The nine items cover general quality of life, patients' perceived sexual life status and interference by BPH of activities. Validation of the BPHQoL9 indicates that it is practical, reliable and responsive to change with treatment. In actual use, for the domain on perceived sexual life, the patient would complete the chart shown in Figure 1 .
Discussion
It is important that the term 'sexuality' does not become a catchall term to cover a multitude of sexual and nonsexual problems. This is essential for accurate assessment of the patient's condition. Although all of the questionnaires discussed previously have been adapted and validated, none of them measure the same items and the scoring systems differ for each one. The measurement of sexuality falls a long way behind that of measuring urinary tract symptoms. For sexuality, there is no equivalent questionnaire to the International Prostate Symptom Score (I-PSS), ie a self-administered questionnaire allowing the measurement in a simple, reproducible and comparative method of the different domains of sexuality as they are perceived by the patient. Even in clinical trials, sexual disorders are sometimes only assessed through adverse event reporting by the patient. It is important that adapted and validated self-administered questionnaires are systematically used in clinical trials. In current practice, sexuality is one of the most difficult areas to discuss with the patient and consequently questionnaires to assess sexuality should be simple and easy to understand.
The best treatment for a patient is certainly one that improves both symptoms and quality of life. For the increasing percentage of patients who are sexually active, sexuality is an important dimension that is currently still underestimated. For a comparable efficacy, it is important that in choosing a treatment its impact on sexuality is taken into account.
Conclusions
In terms of measuring sexual dysfunction, it is important to clarify what is being measured and indeed what needs to be measured. It may be necessary to use more specific terminology and stop using the vague term, 'sexuality'. The numerous instruments that are currently in use for assessment for sexual dysfunction should be harmonised so that comparisons between treatments and patient groups can be made more easily. Further tools should be developed that provide a better objective measure of the different domains of male sexuality, not only to diagnose the condition but also to evaluate any treatments that are given to patients.
